An international team of scientists has revealed how rogue rings of DNA that float outside of our chromosomes – known as extrachromosomal DNA, or ecDNA – can drive the growth of a large proportion of glioblastomas, the most common and aggressive adult brain cancer.
A study reveals that increased walking volume lowers the risk of chronic low back pain, highlighting the importance of daily physical activity for prevention.
NYU Langone Health’s Perlmutter Cancer Center announces the arrival of acclaimed cancer leaders Anirban Maitra, MD, and Manuel Hidalgo, MD, as co-directors of a new Gastrointestinal (GI) Cancer Center.
Investigators at Johns Hopkins Medicine report new evidence that the protein Piezo1 controls skin growth by detecting when skin is stretched and then coordinating the metabolic and immune changes necessary for growth.
In the quest to address infertility, Cornell University researchers have developed a groundbreaking device that could simplify and automate oocyte cumulus removal, a critical step in assisted reproductive technologies.
Axxam S.p.A., a premier provider of integrated early drug discovery services, and B’SYS GmbH, a specialist in ion channel biology, are pleased to announce a strategic collaboration focused on enabling access to validated ion channel cell lines for hit and lead identification through high-throughput electrophysiological screening.
Cancer immunotherapy, which primes the body’s immune system to fight off tumors, has historically focused on harnessing T cells’ natural ability to recognize and attack cancer cells.
BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).
Research indicates that creatine may enhance muscle strength and size in Alzheimer’s patients, suggesting a viable approach for mitigating muscle loss.
Biosero, a BICO company and developer of integrated laboratory automation solutions, signed a master service agreement with a global pharma company in August 2025 and has now received the first purchase orders of a total value of 15.2 MUSD.